CXCR4 a G-protein coupled receptor is an important pharmaceutical target in a variety of diseases including HIV and many forms of cancer. CXCR4 is therefore an important pharmaceutical target but besides the cognate agonist SDF-1 only synthetic antagonists/inverse agonists are targeting CXCR4 with pertinent affinities. CXCR4 has important household functions; those antagonists lead to the emergence of significant adverse drug effects. We recently describe nanomolar CXCR4 agonists [1] where the SDF-1 N-terminus was grafting to the inverse agonist T140 [2] (Figure 1 ). In order to translate these peptidic compounds into peptidomimetic agonists, permitting eventual pharmaceutical applications, the present contribution describes the SAR of the grafted SDF-N-terminus in order to pinpoint the agonist-antagonist transition and to determine the peptidomimetic transition strategies.
Introduction
CXCR4 a G-protein coupled receptor is an important pharmaceutical target in a variety of diseases including HIV and many forms of cancer. CXCR4 is therefore an important pharmaceutical target but besides the cognate agonist SDF-1 only synthetic antagonists/inverse agonists are targeting CXCR4 with pertinent affinities. CXCR4 has important household functions; those antagonists lead to the emergence of significant adverse drug effects. We recently describe nanomolar CXCR4 agonists [1] where the SDF-1 N-terminus was grafting to the inverse agonist T140 [2] (Figure 1 ). In order to translate these peptidic compounds into peptidomimetic agonists, permitting eventual pharmaceutical applications, the present contribution describes the SAR of the grafted SDF-N-terminus in order to pinpoint the agonist-antagonist transition and to determine the peptidomimetic transition strategies.
Results and Discussion
Peptides were synthesized using the Fmoc-based solid-phase strategy; as a first step the synthesis of the (Lys14 [ε-DDE]) T140 was completed and SDF-1 N-terminus grafted in position 14. Peptides were cleaved, purified, analyzed by HPLC indicating a purity greater than 97%, and molecular weights were confirmed by LC/MS. Peptide affinities were determined on CXCR4 binding assays (data not shown). Chemotactic activities were evaluated on Transwell migration assays on pre-B lymphocytes (REH cells). Signaling pathway Gi/o was evaluated with EPAC BRET assay on cAMP inhibition (Cotransfected HEK293 with HA-CXCR4 and EPAC Biosensor). The relative importance of each N-terminal SDF-1 residues was evaluated by an Alanine scan and chemotactic activity screened by Transwell assays. Position 1, 2, 3 and 7 seems to be critical for the conservation of the chemotactic activity ( Figure 2 ): all these alanine containing compounds were in fact competitive antagonists (data not shown). Position 1 and 2 are reputed to be essential for biological activity [3] therefore position 3 was studied. Screen in position 3 shown that hydrophobic amino acids with the ability to make π-stacking in position 3 like Trp, 2-Nal and Bpa (p-Benzoylphenylalanine) gave potent chemotactic chimeras with a maximum of migration at 10nM and efficacy comparable to SDF-1 (Max. of migration at 1nM: 53%). Tert-Leucine replacement gave partial chemotactic agonist.
In order to progressively transform into peptidomimetic sequence in position 8 to 10 of SDF-1, N-terminus was replaced by a PEG linker. PEG insertion combined with hydrophobic modification in position 3 (i.e. Bpa) gave potent chemotactic agonist (Figure 3 ).
CXCR4 signals through Gi/o -therefore we evaluated the profile of our ligands using EPAC BRET assays [4] . All full chemotactic agonists were full agonists on the Gi/o pathway whereas partial agonists behaved like partial agonists (Figure 4 ).
Through this study, we have highlighted several important points for the conservation of the agonistic nature of our chimeras. The Alanine scan emphasizes the importance of residues like Lys 1 , Pro 2 , Val 3 and Tyr 7 and thus restricts the transition to peptidomimetic structures.
The position 3 of our chimeras seems to tolerate hydrophobic structural changes with the ability to make π-stacking. Hydrophobic amino acid in position 3 seems to positively modulate the agonistic behavior. Excessive flexibility appears to place the side chain into a less favorable conformation than the one required to induce the activation of the CXCR4 receptor. Nevertheless, some structural modifications (i.e. PEG) in position 8 to 10 combined with highly hydrophobic modification (i.e. BenzoylPhenylAlanine) in position 3 give potent CXCR4 agonist. Chemotaxis seems to correlate with the Gi/o pathway. 
